OBJECTIVES: The aim of this study was to evaluate associations of 25-hydroxyvitamin D (25-OHD) and parathyroid hormone (PTH) concentrations separately and in combination with incident cardiovascular events and mortality during 14 years of follow-up in the CHS (Cardiovascular Health Study). BACKGROUND: Vitamin D deficiency and PTH excess are common in older adults and may adversely affect cardiovascular health. METHODS: A total of 2,312 participants who were free of cardiovascular disease at baseline were studied. Vitamin D and intact PTH were measured from previously frozen serum using mass spectrometry and a 2-site immunoassay. Outcomes were adjudicated cases of myocardial infarction, heart failure, cardiovascular death, and all-cause mortality. RESULTS: There were 384 participants (17%) with serum 25-OHD concentrations <15 ng/ml and 570 (25%) with serum PTH concentrations ≥ 65 pg/ml. After adjustment, each 10 ng/ml lower 25-OHD concentration was associated with a 9% greater (95% confidence interval [CI]: 2% to 17% greater) relative hazard of mortality and a 25% greater (95% CI: 8% to 44% greater) relative hazard of myocardial infarction. Serum 25-OHD concentrations <15 ng/ml were associated with a 29% greater (95% CI: 5% to 55% greater) risk for mortality. Serum PTH concentrations ≥ 65 pg/ml were associated with a 30% greater risk for heart failure (95% CI: 6% to 61% greater) but not other outcomes. There was no evidence of an interaction between serum 25-OHD and PTH concentrations and cardiovascular events. CONCLUSIONS: Among older adults, 25-OHD deficiency is associated with myocardial infarction and mortality; PTH excess is associated with heart failure. Vitamin D and PTH might influence cardiovascular risk through divergent pathways.
OBJECTIVES: The aim of this study was to evaluate associations of 25-hydroxyvitamin D (25-OHD) and parathyroid hormone (PTH) concentrations separately and in combination with incident cardiovascular events and mortality during 14 years of follow-up in the CHS (Cardiovascular Health Study). BACKGROUND:Vitamin D deficiency and PTH excess are common in older adults and may adversely affect cardiovascular health. METHODS: A total of 2,312 participants who were free of cardiovascular disease at baseline were studied. Vitamin D and intact PTH were measured from previously frozen serum using mass spectrometry and a 2-site immunoassay. Outcomes were adjudicated cases of myocardial infarction, heart failure, cardiovascular death, and all-cause mortality. RESULTS: There were 384 participants (17%) with serum 25-OHD concentrations <15 ng/ml and 570 (25%) with serum PTH concentrations ≥ 65 pg/ml. After adjustment, each 10 ng/ml lower 25-OHD concentration was associated with a 9% greater (95% confidence interval [CI]: 2% to 17% greater) relative hazard of mortality and a 25% greater (95% CI: 8% to 44% greater) relative hazard of myocardial infarction. Serum 25-OHD concentrations <15 ng/ml were associated with a 29% greater (95% CI: 5% to 55% greater) risk for mortality. Serum PTH concentrations ≥ 65 pg/ml were associated with a 30% greater risk for heart failure (95% CI: 6% to 61% greater) but not other outcomes. There was no evidence of an interaction between serum 25-OHD and PTH concentrations and cardiovascular events. CONCLUSIONS: Among older adults, 25-OHD deficiency is associated with myocardial infarction and mortality; PTH excess is associated with heart failure. Vitamin D and PTH might influence cardiovascular risk through divergent pathways.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: R P van der Wielen; M R Löwik; H van den Berg; L C de Groot; J Haller; O Moreiras; W A van Staveren Journal: Lancet Date: 1995-07-22 Impact factor: 79.321
Authors: Abigail B Shoben; Bryan Kestenbaum; Gregory Levin; Andrew N Hoofnagle; Bruce M Psaty; David S Siscovick; Ian H de Boer Journal: Am J Epidemiol Date: 2011-11-23 Impact factor: 4.897
Authors: Cassianne Robinson-Cohen; Michael Shlipak; Mark Sarnak; Ronit Katz; Carmen Peralta; Bessie Young; Andrew N Hoofnagle; Moyses Szklo; Joachim H Ix; Bruce M Psaty; Ian H de Boer; Bryan Kestenbaum; Nisha Bansal Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith Journal: Am J Kidney Dis Date: 2015-02-26 Impact factor: 8.860
Authors: Daniel V Dudenkov; Kristin C Mara; Tanya M Petterson; Julie A Maxson; Tom D Thacher Journal: Mayo Clin Proc Date: 2018-05-02 Impact factor: 7.616
Authors: Jerome L Fleg; Daniel E Forman; Kathy Berra; Vera Bittner; James A Blumenthal; Michael A Chen; Susan Cheng; Dalane W Kitzman; Mathew S Maurer; Michael W Rich; Win-Kuang Shen; Mark A Williams; Susan J Zieman Journal: Circulation Date: 2013-10-28 Impact factor: 29.690
Authors: Á Aceña; A M Pello; R Carda; Ó Lorenzo; M L Gonzalez-Casaus; L M Blanco-Colio; J L Martín-Ventura; J Palfy; M Orejas; R Rábago; E Gonzalez-Parra; I Mahíllo-Fernández; J Farré; J Egido; J Tuñón Journal: J Nutr Health Aging Date: 2016 Impact factor: 4.075
Authors: Cassianne Robinson-Cohen; Leila R Zelnick; Andrew N Hoofnagle; Pamela L Lutsey; Gregory Burke; Erin D Michos; Steven J C Shea; Russell Tracy; David S Siscovick; Bruce Psaty; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: A J van Ballegooijen; M Visser; M F Cotch; A E Arai; M Garcia; T B Harris; L J Launer; G Eiríksdóttir; V Gudnason; I A Brouwer Journal: J Clin Endocrinol Metab Date: 2013-04-12 Impact factor: 5.958
Authors: P Ameri; M Canepa; Y Milaneschi; P Spallarossa; G Leoncini; F Giallauria; J B Strait; E G Lakatta; C Brunelli; G Murialdo; L Ferrucci Journal: J Intern Med Date: 2012-11-12 Impact factor: 8.989